New clinical trial to study long-term progression of brain and spine cancers

Posted: Aug 8, 2016

Dr. Mark Gilbert, Chief, Neuro-Oncology Branch, describes an ambitious new clinical trial that, for the first time, will study the long-term progression of brain and spine cancers. The 10,000 patient trial is the largest of its kind and will follow patients throughout the course of their disease. In addition to identifying optimal treatments for common brain and spine cancers, the study focuses on treatment discovery for rare, overlooked cancers.

New clinical trial to study long-term progression of brain and spine cancers

Clinical trial studies combination effect on small cell lung cancer

Posted: Jul 27, 2016

Dr. Anish Thomas, Staff Clinician in the Thoracic and GI Oncology Branch is conducting a clinical trial for small cell lung cancer (SCLC).

Clinical trial studies combination effect on small cell lung cancer

Clinical trial combines enzalutamide with immunotherapy for advanced prostate cancer

Posted: Jul 11, 2016

Dr. Ravi Madan, Clinical Director of the Genitourinary Malignancies Branch, is conducting a clinical trial for men who have metastatic prostate cancer but have not yet been treated with chemotherapy, abiraterone or enzalutamide.

Clinical trial combines enzalutamide with immunotherapy for advanced prostate cancer

New clinical trial combines LMB-100 with nab-paclitaxel for metastatic or locally advanced pancreatic cancer

Posted: Jul 8, 2016

Christine Alewine, Lasker Scholar, in the Laboratory of Molecular Biology is conducting a clinical study for patients with pancreatic cancer using a new immunotoxin drug, called LMB-100. It is a targeted immunotherapy that delivers a toxin to cancer cells that make a protein called mesothelin that is made by most pancreatic cancers.

New clinical trial combines LMB-100 with nab-paclitaxel for metastatic or locally advanced pancreatic cancer

Trial of Pembrolizumab for HIV-Positive Patients with Recurrent or Refractory Cancer

Posted: Jun 8, 2016

The HIV and AIDS Malignancy Branch is collaborating with the Cancer Immunotherapy Trials Network to conduct a phase I clinical trial of pembrolizumab (Keytruda®) in HIV-positive patients with a variety of recurrent or refractory cancers.

Trial of Pembrolizumab for HIV-Positive Patients with Recurrent or Refractory Cancer

Pages